NovaBay Bets $134M on DeFi with 8.78% SKY Token Stake
In a radical corporate transformation, NovaBay Pharmaceuticals (NBY) has rebranded as Stablecoin Development Corporation (SDEV) and pivoted its entire business model to cryptocurrency. The company secured $134 million in a private placement from investors including Framework Ventures and Tether Investments to fund the move. On March 23, 2026, SDEV announced it had acquired 2.06 billion SKY tokens, which constitutes approximately 8.78% of the governance token's total supply for the Sky protocol.
The acquisition makes the former pharmaceutical firm a dominant player in the decentralized finance (DeFi) protocol. The company's holdings, now valued at around $147 million, were accumulated through a mix of direct allocation from the financing deal and open-market purchases at an average price of $0.065 per token. The market reacted with modest optimism, as shares of the newly named SDEV climbed 5% on the news.
Staking Yields Exceed 10% as Firm Secures Governance Power
The immediate financial logic for the pivot hinges on high-yield staking. SDEV is actively staking its SKY holdings, generating returns that the company states exceed 10% annually—a stark contrast to its prior unprofitable operations in the antimicrobial eye care market. The strategy is already proving productive, with the firm reporting it has earned 26.6 million SKY tokens in staking rewards as of March 16, 2026.
This massive stake provides more than just yield; it grants significant influence. SKY is the governance token for the Sky protocol, the decentralized platform (formerly MakerDAO) that issues the USDS stablecoin. By controlling 8.78% of the supply, SDEV gains substantial voting power over the protocol's rules, from collateral requirements to fee structures. This positions the company to potentially steer the protocol's development.
A Strategic Pivot or High-Risk Yield Farm?
Investors are now assessing whether this is a sophisticated strategic maneuver or a speculative treasury play with extreme risk. The bull case points to a potential long-term strategy where SDEV uses its governance power to integrate the USDS stablecoin into regulated healthcare payment systems for clinical trials or insurance settlements. Such a move would represent a landmark use case for DeFi in traditional industry.
The bear case is equally compelling. SDEV, a micro-cap company, has concentrated its entire balance sheet into a single, volatile DeFi token. This creates immense concentration risk, as any attempt to liquidate its massive position would likely crash the token's price. Furthermore, the company exposes its shareholders to the uncertain regulatory landscape surrounding DeFi and governance tokens. Whether this pivot becomes a model for corporate finance or a cautionary tale will depend on if SDEV leverages its stake for genuine strategic integration or simply operates as a high-risk yield farm.
